Novo Nordisk said on September 21 that its experimental CagriSema treatment produced greater weight loss than Eli Lilly's rival in a late-stage study involving people with type 2 diabetes, Reuters reported.
Novo says CagriSema produced greater weight loss than Lilly rival in a diabetes study
Novo Nordisk reported late-stage results comparing its next-generation obesity candidate with Eli Lilly's treatment in people with type 2 diabetes.
